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Background. Hyperhomocysteinemia is a recognised independent risk factor in the genesis of atherosclerotic diseases.
However, very little is known about the relationship between homocysteine and abdominal aortic aneurysm (AAA).
Vitamins, namely B12 and folic acid have been implicated in the regulation of plasma homocysteine levels. However, there has
been no prospective study that has analysed the relationship of AAA and plasma homocysteine in light of serum vitamin
levels.
Aims. To study the relationship between plasma homocysteine, serum B12 and folic acid levels, and AAA.
Method. Case control study including 38 AAA patients and 36 controls. Fasting homocysteine, B12 and folic acid were
determined in serum separated within 1 h of blood collection using a fluorescence polarisation immunoassay technique
(FPIA).
Results. Twenty-six (68%) of the AAA patients had elevated levels of homocysteine compared to 2 (6%) in the case control
group. The mean homocysteine level in the AAA group was 19.4 mmol/L (SE ^ 1.1) (95% CI 17.17–21.65) and in the
control group was 10.9 mmol/L (SE ^ 1) (95% CI 9.95–11.88) (p , 0.001). Mean vitamin B12 levels in the AAA and
the controls was 332.11 pg/L (SE ^ 16.44) and 414.33 pg/L (SE ^ 19.72), respectively (p , 0.004). Mean folic acid in the
AAA was 8.02 (SE ^ 0.71) and the control was 9.8 hgm/L (SE ^ 0.69), (ns).
Conclusion. This study confirms significantly higher levels of plasma homocysteine in AAA patients but lower levels of B12.
Use of supplemental vitamins that should lower plasma homocysteine may modify vascular disease progression. Clinical
trials in this direction are warranted.
Key Words: Abdominal aortic aneurysm; Total plasma homocysteine; Vitamin B12 and folic acid.
Introduction
Homocysteine biochemistry is complex, with the
plasma total homocysteine (THCY) being the sum of
homocyst(e)ine, and its oxidised forms homocystine,
and the homocysteine—cystine mixed disulphide, in
free and protein bound forms.1 It is a sulphur
containing amino acid, elevated plasma levels of
which are referred to as hyperhomocysteinemia. It is
an intermediary product in methionine metabolism.
The transfer of methyl group from methionine is an
important step in the metabolism of nucleic acids, fats,
and high-energy bonds. When methionine donates its
methyl group, homocysteine is formed. The majority
of homocysteine is recycled in a transmethylation
reaction involving vitamin B12 and folic acid while a
smaller amount is metabolised by transulphuration
involving vitamin B6. Hence the vitamin intake and
serum vitamin levels play an important part in the
regulation of plasma homocysteine levels.
It was the observation that patients presenting with
homocystinuria, an autosomal recessive metabolic
disorder leading to raised plasma homocystine, also
displayed premature vascular disorders that drew
attention to the causal relationship between vascular
disorder and homocystine.2 – 4 It was subsequently
shown in experimental models that intravenous
infusion of homocysteine caused endothelial vascular
injury and atherosclerosis.5 Further studies demon-
strated elevated levels of homocysteine as a risk factor
in the causation of coronary artery,6 cerebrovascular7
and peripheral vascular diseases,8 independent of
other risk factors such as age, gender, lipids, lipopro-
teins, cholesterol, hypertension and smoking.9 – 11
There is currently very little data that has examined
the possible relationship between plasma homocys-
teine and the development of abdominal aortic
aneurysm (AAA)12 and serum vitamin levels. There-
fore, this study was designed to investigate possible
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relationship between THCY, levels of serum vitamin
B12 and folic acid, and AAA.
Materials and Methods
Study design
This was a case-control study in which patients were
selected into two groups. Group 1 (AAA group)
consisted of patients with AAA (AP diameter
$3 cm) diagnosed on ultrasound scan (USS) (using
Gray-scale B-mode images) of the abdomen. Group 2
(Control group) consisted of individuals free from any
known AAA (excluded using an ultrasound abdomi-
nal scan), and free of obvious peripheral vascular
disease, assessed clinically and on the basis of ankle
brachial ratio .0.9. These individuals were randomly
selected from the open access aneurysm USS screening
programme.
Exclusion criteria
Patients who had not fasted for 8 h prior to blood
sample withdrawal.
Patients who were taking any vitamin supplemen-
tation—prescribed or self medicated.
Patients whose blood sample could not be centrifuged
for separation of serum within 1 h of collection.
Collection of samples
Approximately 4 mL of venous blood were taken from
the antecubital vein into a vacutainer tube containing
EDTA (Beckton-Dickinson). The sample was immedi-
ately transferred to an ice bag and taken to the
biochemistry laboratory. Within 60 min of collection,
the blood samples were centrifuged at 3000 revolu-
tions per min (rpm) for 5 min, to separate the
supernatant serum from the cells. This serum was
stored at 280 8C prior to the analysis of plasma
homocysteine concentration.
For vitamin B12 and folate analysis, serum was
obtained from a second EDTA tube using identical
methodology.
Biochemical analysis
Homocysteine
Fasting homocysteine plasma levels were analysed
using a fluorescence polarisation immunoassay (FPIA)
technique for the quantitative measurement of total
homocysteine (Imx system, Axis Biochemicals, ASA
Ulvenvein, Norway). Plasma homocysteine levels
.15 mmol/L were taken as abnormally elevated.
Vitamins
The vitamins B12 and folic acid were measured with an
automated immunoassay analyser, using chemilumi-
nescence detection technique (Bayer ACS 180, New-
bury, Berkshire, UK). The normal range of vitamin B12
was taken as 160–350 pg/L and that of folic acid was
3.5–15 hg/L.
In addition, the urine specific gravity and the
haematocrit were ascertained to facilitate correction
for concentration factor difference between the two
groups that could have been induced due to overnight
fasting.
Statistical analysis
A one-way analysis of variance (ANOVA) was used to
test the significance of differences in plasma total
homocysteine, vitamin B12 and folic acid between the
AAA and control groups. Data are presented as
mean ^ standard errors (SE) of the mean. Differences
were considered significant at the 95% level ðP , 0:05Þ:
Difference in the characteristics or risk factors in the
AAA and control groups were analysed using Chi-
square and Fisher’s exact test. All statistical tests were
performed using SPSS computer software package.
Results
There were a total of 74 patients, 38 in the AAA group
with a mean age of 70 years (range 53–79), and 36 in
the control group with a mean age of 66 years (range
48–79).
The characteristics of patients in the AAA group
and the control group are summarised in Table 1.
Twenty-six (68%) of the AAA patients had elevated
Table 1. Characteristics of patients in the AAA group and the
control group.
Characteristics AAA Control ‘p’
Hypertension 13 12 0.955
Hyperlipidaemia 4 3 0.769
Diabetes 3 4 0.677
COAD 3 0 0.097
Cardiac disease 24 9 0.038
Stroke 5 1 0.130
Family history of AAA 4 0 0.057
Constipation 8 2 0.087
Cancer 3 3 0.949
Benign hypertrophy of prostate 8 6 0.690
Smoking 13 12 0.955
Alcohol 7 9 0.581
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levels of homocysteine compared to 2 (6%) in the case
control group (Fig. 1). The mean THCY concentration
for patients in the AAA group was 19.4 mmol/L (95%
CI 17.17–21.65) and for patients in the control group
10.9 mmol/L (95% CI 9.95 –11.88) (Table 2). The
difference between the two groups was highly
significant ðp , 0:001Þ: However, there was no corre-
lation between the size of the AAA and the plasma
THCY concentration (Fig. 2). In the AAA group the
mean homocysteine levels for patients $70 years
compared to those,70 years was 19.2 and 19.6 mmol/
L, respectively (p ¼ ns). For the control group these
values were 11.3 vs. 10.3 mmol/L (ns).
There were 35 males and 3 females in the
AAA group and 21 males and 15 females in the
control group. The mean homocysteine for males in
AAA group was 19 mmol/L and for females was
23.4 mmol/L. The mean homocysteine for males and
females in the control group was 11.5 vs. 10.2 mmol/L,
respectively. These differences were not significant.
Thus there was no correlation between homocysteine
levels and age for either the AAA or control groups
nor were there any relationship between gender for
either group.
The mean vitamin B12 in the AAA group was
332.11 pg/mL (SE ^ 16.44) and in the control group
was 414.33 pg/mL (SE ^ 19.72). The difference
between the two groups was highly significant ðp ,
0:004Þ: The mean folic acid in the AAA group was
8.02 hg/mL (SE ^ 0.71) and control was 9.8 hg/mL
(SE ^ 0.69). However, there was no statistical differ-
ence in the folic acid levels between the two groups.
The urinary specific gravity and the haematocrit
were similar in the two groups (1015 in AAA group
and 1018 in control group), indicating the compar-
ability of the two groups in terms of hydration status.
Discussion
The primary finding of this study is that THCY levels
of patients with AAA are significantly higher than
those of the control group. The importance of homo-
cysteine in coronary artery disease, cerebrovascular
disease and peripheral vascular disease is well
documented.6 – 8 However, current literature on the
role of homocysteine in the aetiopathogenesis of AAA
is limited.12 – 15 Moreover, 26 of the 38 (68%) patients in
the AAA group had raised plasma homocysteine
compared to only two of the 34 (6%) patients in the
control group. Authors have found a prevalence of
hyperhomocysteinemia in 40% patients with periph-
eral vascular disease9 and 48% in patients suffering
from AAA.12 Our data suggests that there may be a
higher prevalence of hyperhomocysteinemia in AAA
than previously believed. Our data of a 6% prevalence
of hyperhomocysteinemia in control population is
very similar to 5 and 7% reported in previous
studies.16,17 In the AAA group, we found no corre-
lation between the size of the AAA and the levels of
homocysteine. Though there is evidence that homo-
cysteine is associated with aortic atherosclerosis18 and
AAA,12 it is possible that hyperhomocysteinemia
initiates the atherosclerosis, but once an aneurysm is
established any subsequent dilatation is more of a
mechanical event in relation to the blood pressure in
the AAA, and with time the AAA progressively
dilates.
Homocysteine causes elastolysis and damage to
tunica media by activation of matrix metalloprotein-
ases (MMP-2) and serine elastase; damage to the
endothelium by impaired production of nitric oxide
leading to atherosclerosis and aneurysm formation.19–22
Since elevated plasma homocysteine levels bear an
inverse relation to the serum vitamins, plasma homo-
cysteine levels may be lowered by supplemental
vitamins thus preventing AAA formation—‘a risk
factor reduction’.
Four patients in the AAA group had familial history
of AAA against none in the control group. This raises
the question whether the familial nature of AAA is due
to higher plasma homocysteine, as hyperhomocystei-
nemia can itself be familial. It is well known that
patients with homocysteinuria, an autosomal meta-
bolic disorder leading to elevated plasma homocys-
teine, develop premature vascular disorder.2,3
Plasma homocysteine levels, with reference to
vascular disease, have been found to increase with
age in some23,24 but not all the previous studies.25,26
We found no such association when we analysed the
plasma homocysteine levels in relation to age, in either
the AAA or the control group. There may have been
Fig. 1. Plasma homocysteine (THCY) (mmol/L) in the
controls, and patients with AAA. The transverse line in the
scatterplot represents the median value.
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other factors at play such as nutrition status, in terms
of methionine-rich diet, in the younger groups of
patient.
Similarly, the homocysteine levels have been shown
to be greater in male than female subjects with
vascular diseases by most authors27 – 29 but some
have shown no difference or marginally higher
homocysteine levels in females than in males.30,31
Interestingly, in the AAA group in our study, the mean
homocysteine levels in males were lower in compari-
son to females but this failed to reach statistical
significance. Moreover, any meaningful conclusion
about gender differences in homocysteine levels
cannot be derived from our data due to the small
sample size of the female population.
It is known that enzymatic reactions involving folic
acid and vitamin B12 helps in the formation of
methionine by remethylation of excess homocysteine,
thus preventing hyperhomocysteinemia. Vitamin B6
assists in the breakdown of excess homocysteine into
cysteine in an irreversible trans-sulphuration reaction
and thus maintains normal homocysteine levels.
Previous studies have examined the relationship
between folic acid, B12 and their influence on the
homocysteine levels.28,32 – 34 It is well documented that
hyperhomocysteinemia is associated with deficiencies
of vitamin B12 and folate levels. The strongest inverse
correlate for patients with coronary disease being
between homocysteine and folate.35 – 37
We found that the mean vitamin B12 levels were
significantly higher in the AAA group than the control
group, although there was no such relationship for
folic acid. It is difficult to explain as to why vitamin B12
were generally high. The dietary habits of the subjects
that could have influenced the serum vitamin levels,
were not known and this we think are one drawback of
this study. Perhaps the baseline calibration needed to
be re-assessed or the normal range re-defined. Despite
this, the vitamin B12 levels were significantly higher in
the control group vs. the AAA group.
The folic acid levels were reduced in the AAA
group vs. the control group but failed short of reaching
the statistical significance. Perhaps, a larger sample
size may have made this more apparent.
Our data suggests that the homocysteine levels are
more susceptible to changes in vitamin B12 levels than
folic acid levels although, previous studies have
shown folate deficiency may be more important than
vitamin B12 deficiency in influencing the plasma
homocysteine levels and vascular diseases.35,36
In conclusion, we have demonstrated a positive
correlation between the presence of AAA and elevated
plasma homocysteine. In order to confirm the relation-
ship, long-term population studies will be required to
establish whether patients at high risk of AAA can be
prevented from developing aneurysm by selected
vitamin supplements.
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